Cogent Biosciences (COGT) Equity Ratio (2017 - 2026)
Cogent Biosciences' Equity Ratio history spans 10 years, with the latest figure at 0.67 for Q1 2026.
- Quarterly Equity Ratio fell 12.79% to 0.67 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.67 through Mar 2026, down 12.79% year-over-year, with the annual reading at 0.68 for FY2025, 13.16% down from the prior year.
- Equity Ratio came in at 0.67 for Q1 2026, down from 0.68 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2022 to a low of 0.56 in Q2 2025.
- The 5-year median for Equity Ratio is 0.85 (2023), against an average of 0.8.
- Year-over-year, Equity Ratio increased 4.43% in 2024 and then tumbled 35.01% in 2025.
- Cogent Biosciences' Equity Ratio stood at 0.85 in 2022, then fell by 3.25% to 0.82 in 2023, then dropped by 4.97% to 0.78 in 2024, then decreased by 13.16% to 0.68 in 2025, then fell by 0.85% to 0.67 in 2026.
- Per Business Quant, the three most recent readings for COGT's Equity Ratio are 0.67 (Q1 2026), 0.68 (Q4 2025), and 0.71 (Q3 2025).